Kidd’s Disease (X‑linked Agammaglobulinemia)

What is Kidd’s disease (X‑linked agammaglobulinemia)?

Kidd’s disease, more formally known as **X‑linked agammaglobulinemia (XLA)**, is a rare inherited disorder of the immune system. It is characterized by a near‑absence of mature B‑cells, the white‑blood cells that produce antibodies (immunoglobulins). Because antibodies are essential for fighting bacterial infections, people with XLA experience recurrent, often severe, infections beginning in early childhood.

The condition is called “X‑linked” because the defective gene (BTK – Bruton’s Tyrosine Kinase) is located on the X chromosome. Males, who have only one X chromosome, are therefore affected almost exclusively. Female carriers usually have no symptoms but can pass the gene to their children.

First described by Dr. Ogden Bruton in 1952, XLA has historically been referred to as “Bruton’s agammaglobulinemia.” The eponym “Kidd’s disease” is sometimes used in older textbooks, but the modern, widely‑accepted term is X‑linked agammaglobulinemia.

Common Causes

Because XLA is a genetic disorder, the primary cause is a mutation in the BTK gene. However, several other conditions can lead to a similar laboratory picture of low immunoglobulins (secondary agammaglobulinemia). The table below lists the most common genetic and acquired causes.

• BTK gene mutation – loss‑of‑function variants impair B‑cell development.
• Other X‑linked immunodeficiency genes – e.g., IKZF1 (IKAROS) deficiency.
• Autosomal recessive agammaglobulinemia – mutations in μ heavy chain (IGHM) or lambda5 (IGLC1).
• Common variable immunodeficiency (CVID) – heterogeneous group of disorders with low antibody production.
• Secondary causes – chemotherapy, rituximab therapy, or long‑term corticosteroid use that depletes B‑cells.
• Protein‑losing enteropathies – severe gastrointestinal disease that causes loss of immunoglobulins.
• HIV infection – can lead to reduced B‑cell numbers and hypogammaglobulinemia.
• Severe combined immunodeficiency (SCID) – rare forms involve B‑cell dysfunction.
• Congenital infections – such as cytomegalovirus (CMV) that damage bone marrow.
• Chronic lymphocytic leukemia (CLL) – may cause secondary hypogammaglobulinemia.

In the context of “Kidd’s disease,” the BTK mutation is by far the most common and definitive cause.

Associated Symptoms

Because antibodies are missing, the immune system cannot adequately clear encapsulated bacteria. Typical clinical features include:

• Recurrent sinopulmonary infections – pneumonia, bronchitis, sinusitis, otitis media.
• Frequent gastrointestinal infections – often caused by Giardia lamblia or Campylobacter.
• Skin infections – impetigo, cellulitis, or chronic eczema‑like rashes.
• Abscess formation – especially in the lungs or soft tissue.
• Low or absent lymph nodes and tonsils – due to paucity of B‑cells.
• Delayed growth or poor weight gain in early childhood.
• Chronic fatigue and decreased exercise tolerance due to repeated infections.
• In rare cases, autoimmune phenomena (e.g., autoimmune hemolytic anemia) may develop.

Symptoms typically start after 6–12 months of age, when maternal IgG wanes and the child’s own antibody production is required.

When to See a Doctor

Because infections can progress quickly without adequate antibodies, prompt medical attention is essential. Seek care if you notice any of the following:

• Fever > 38.5 °C (101.3 °F) lasting more than 48 hours.
• Persistent cough, shortness of breath, or chest pain.
• Recurrent sinus infections (three or more per year) or chronic sinus drainage.
• Severe or bloody diarrhea, especially after travel.
• Unexplained weight loss or failure to thrive in a child.
• Redness, swelling, or warmth over any body part suggesting an abscess.
• New onset of neurological symptoms (headache, confusion, stiff neck) – could indicate meningitis.
• Any sign of an allergic reaction after receiving immunoglobulin therapy.

Early evaluation can prevent complications such as lung damage (bronchiectasis) and irreversible growth impairment.

Diagnosis

Diagnosing XLA involves a combination of clinical suspicion, laboratory testing, and genetic confirmation.

1. Detailed medical history & physical exam

• Frequency, type, and severity of infections.
• Family history of immunodeficiency (especially male relatives).
• Examination for absent or small lymph nodes and tonsils.

2. Laboratory studies

• Serum immunoglobulin levels – markedly reduced IgG, IgA, and IgM.
• Peripheral blood flow cytometry – low (<2 %) CD19⁺ or CD20⁺ B‑cells.
• Complete blood count (CBC) – usually normal white‑cell count but may show neutrophilia during infection.
• Specific antibody response testing – poor response to vaccines (e.g., tetanus, pneumococcal).

3. Genetic testing

Sequencing of the BTK gene confirms the diagnosis in > 90 % of cases. Testing is also valuable for carrier detection in female relatives.

4. Imaging (when indicated)

• Chest X‑ray or CT scan to assess for bronchiectasis.
• Sinus CT if chronic sinusitis is present.

Guidelines from the American Academy of Allergy, Asthma & Immunology (AAAAI) and the European Society for Immunodeficiencies (ESID) recommend confirming XLA with both immunophenotyping and genetic analysis before initiating long‑term therapy.^1,2

Treatment Options

Because the underlying genetic defect cannot be reversed (except by experimental gene therapy), treatment focuses on replacing missing antibodies and preventing infections.

1. Immunoglobulin replacement therapy (IGRT)

• Intravenous immunoglobulin (IVIG) – 400–600 mg/kg every 3–4 weeks.
• Subcutaneous immunoglobulin (SCIG) – 100–200 mg/kg weekly; offers greater flexibility and fewer systemic reactions.
• Goal: maintain trough IgG levels > 500 mg/dL to reduce infection risk.

IGRT has dramatically improved survival; most patients now live into adulthood with a normal life expectancy when therapy is adhered to.

2. Prompt antimicrobial therapy

• Empiric broad‑spectrum antibiotics for suspected bacterial infections (e.g., amoxicillin‑clavulanate for otitis media, ceftriaxone for pneumonia).
• Tailor antibiotics based on culture results.
• Consider prophylactic antibiotics (e.g., trimethoprim‑sulfamethoxazole) in patients with frequent severe infections, though evidence is mixed.

3. Vaccination strategy

• Avoid live attenuated vaccines (e.g., oral polio, BCG) because of poor antibody response.
• Give inactivated vaccines (influenza, pneumococcal conjugate) to provide whatever limited protection is possible.

4. Management of specific infections

• Giardiasis – metronidazole or tinidazole for 5–7 days.
• Severe viral infections – consider antiviral agents (e.g., acyclovir for HSV) and supportive care.

5. Lifestyle & supportive measures

• Good hand hygiene and avoiding close contact with sick individuals.
• Regular dental care to reduce oral bacterial load.
• Nutrition counseling – adequate protein and calories support overall health.
• Physical activity as tolerated; aerobic exercise may improve lung function.

6. Emerging therapies

Gene therapy using lentiviral vectors to deliver a functional BTK gene is under investigation in early‑phase clinical trials (2023‑2024). While promising, it is not yet approved for routine use.

Prevention Tips

Although the genetic mutation cannot be prevented, many measures reduce infection risk and improve quality of life:

• Adhere to scheduled IGRT—missing doses can rapidly lower IgG levels.
• Wash hands frequently, especially before meals and after using the restroom.
• Stay up‑to‑date on non‑live vaccines (influenza annually, COVID‑19, pneumococcal).
• Avoid crowded places during community outbreaks of respiratory viruses.
• Use protective equipment (mask) in high‑risk settings (e.g., hospitals).
• Promptly treat any infection—even minor sore throats—under a physician’s guidance.
• Screen family members for carrier status if a mutation is identified.
• Educate school personnel and caregivers about the child’s condition and need for immediate medical attention for fevers.

Emergency Warning Signs

---

References:

1. Mayo Clinic. “X‑linked agammaglobulinemia.” Updated 2023. https://www.mayoclinic.org
2. European Society for Immunodeficiencies (ESID). “Guidelines for the diagnosis and management of primary immunodeficiency diseases.” 2022. https://esid.org
3. Cleveland Clinic. “Immunoglobulin Replacement Therapy.” 2024. https://my.clevelandclinic.org
4. National Institutes of Health. “Gene Therapy Clinical Trials for X‑linked Agammaglobulinemia.” ClinicalTrials.gov, accessed June 2026.
5. World Health Organization. “Immunization in persons with primary immunodeficiency.” 2021. https://www.who.int